These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

230 related articles for article (PubMed ID: 27780690)

  • 1. Risk of Atrial Fibrillation and Bleeding Diathesis Associated With Ibrutinib Treatment: A Systematic Review and Pooled Analysis of Four Randomized Controlled Trials.
    Yun S; Vincelette ND; Acharya U; Abraham I
    Clin Lymphoma Myeloma Leuk; 2017 Jan; 17(1):31-37.e13. PubMed ID: 27780690
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ibrutinib increases the risk of hypertension and atrial fibrillation: Systematic review and meta-analysis.
    Caldeira D; Alves D; Costa J; Ferreira JJ; Pinto FJ
    PLoS One; 2019; 14(2):e0211228. PubMed ID: 30785921
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Adverse drug events associated with ibrutinib for the treatment of elderly patients with chronic lymphocytic leukemia: A systematic review and meta-analysis of randomized trials.
    Zhou Y; Lu H; Yang M; Xu C
    Medicine (Baltimore); 2019 Aug; 98(33):e16915. PubMed ID: 31415440
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding.
    Boriani G; Corradini P; Cuneo A; Falanga A; Foà R; Gaidano G; Ghia PP; Martelli M; Marasca R; Massaia M; Mauro FR; Minotti G; Molica S; Montillo M; Pinto A; Tedeschi A; Vitolo U; Zinzani PL
    Hematol Oncol; 2018 Oct; 36(4):624-632. PubMed ID: 29512173
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials.
    Brown JR; Moslehi J; O'Brien S; Ghia P; Hillmen P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Kipps TJ; Coutre S; Dilhuydy MS; Cramer P; Tedeschi A; Jaeger U; Dreyling M; Byrd JC; Howes A; Todd M; Vermeulen J; James DF; Clow F; Styles L; Valentino R; Wildgust M; Mahler M; Burger JA
    Haematologica; 2017 Oct; 102(10):1796-1805. PubMed ID: 28751558
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies.
    Coutre SE; Byrd JC; Hillmen P; Barrientos JC; Barr PM; Devereux S; Robak T; Kipps TJ; Schuh A; Moreno C; Furman RR; Burger JA; O'Dwyer M; Ghia P; Valentino R; Chang S; Dean JP; James DF; O'Brien SM
    Blood Adv; 2019 Jun; 3(12):1799-1807. PubMed ID: 31196847
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
    Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
    Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment: A systematic review and meta-analysis.
    Pellegrini L; Novak U; Andres M; Suter T; Nagler M
    Crit Rev Oncol Hematol; 2021 Mar; 159():103238. PubMed ID: 33515702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk of Major Bleeding with Ibrutinib.
    Mock J; Kunk PR; Palkimas S; Sen JM; Devitt M; Horton B; Portell CA; Williams ME; Maitland H
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):755-761. PubMed ID: 30077698
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictors of atrial fibrillation in ibrutinib-treated CLL patients: a prospective study.
    Reda G; Fattizzo B; Cassin R; Mattiello V; Tonella T; Giannarelli D; Massari F; Cortelezzi A
    J Hematol Oncol; 2018 Jun; 11(1):79. PubMed ID: 29891001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis.
    Brown JR; Moslehi J; Ewer MS; O'Brien SM; Ghia P; Cymbalista F; Shanafelt TD; Fraser G; Rule S; Coutre SE; Dilhuydy MS; Cramer P; Jaeger U; Dreyling M; Byrd JC; Treon S; Liu EY; Chang S; Bista A; Vempati R; Boornazian L; Valentino R; Reddy V; Mahler M; Yang H; Graef T; Burger JA
    Br J Haematol; 2019 Feb; 184(4):558-569. PubMed ID: 30506764
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cardiovascular events reported in patients with B-cell malignancies treated with zanubrutinib.
    Moslehi JJ; Furman RR; Tam CS; Salem JE; Flowers CR; Cohen A; Zhang M; Zhang J; Chen L; Ma H; Brown JR
    Blood Adv; 2024 May; 8(10):2478-2490. PubMed ID: 38502198
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Left atrial abnormality (LAA) as a predictor of ibrutinib-associated atrial fibrillation in patients with chronic lymphocytic leukemia.
    Mato AR; Clasen S; Pickens P; Gashonia L; Rhodes J; Svoboda J; Hughes M; Nabhan C; Ali N; Schuster S; Carver J
    Cancer Biol Ther; 2018 Jan; 19(1):1-2. PubMed ID: 29281559
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
    Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
    Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk of Infection Associated With Ibrutinib in Patients With B-Cell Malignancies: A Systematic Review and Meta-analysis of Randomized Controlled Trials.
    Ball S; Das A; Vutthikraivit W; Edwards PJ; Hardwicke F; Short NJ; Borthakur G; Maiti A
    Clin Lymphoma Myeloma Leuk; 2020 Feb; 20(2):87-97.e5. PubMed ID: 31787589
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Ibrutinib-Associated Atrial Fibrillation.
    Ganatra S; Sharma A; Shah S; Chaudhry GM; Martin DT; Neilan TG; Mahmood SS; Barac A; Groarke JD; Hayek SS; Dani S; Venesy D; Patten R; Nohria A
    JACC Clin Electrophysiol; 2018 Dec; 4(12):1491-1500. PubMed ID: 30573111
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Management of adverse effects/toxicity of ibrutinib.
    Paydas S
    Crit Rev Oncol Hematol; 2019 Apr; 136():56-63. PubMed ID: 30878129
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ibrutinib-related atrial fibrillation: A single center Australian experience.
    Ezad S; Khan AA; Cheema H; Ashraf A; Ngo DTM; Sverdlov AL; Collins NJ
    Asia Pac J Clin Oncol; 2019 Oct; 15(5):e187-e190. PubMed ID: 31250562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recommendations for ibrutinib treatment in patients with atrial fibrillation and/or elevated cardiovascular risk.
    Stühlinger MC; Weltermann A; Staber P; Heintel D; Nösslinger T; Steurer M
    Wien Klin Wochenschr; 2020 Feb; 132(3-4):97-109. PubMed ID: 31414181
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase 3 Trial of Ibrutinib plus Rituximab in Waldenström's Macroglobulinemia.
    Dimopoulos MA; Tedeschi A; Trotman J; García-Sanz R; Macdonald D; Leblond V; Mahe B; Herbaux C; Tam C; Orsucci L; Palomba ML; Matous JV; Shustik C; Kastritis E; Treon SP; Li J; Salman Z; Graef T; Buske C;
    N Engl J Med; 2018 Jun; 378(25):2399-2410. PubMed ID: 29856685
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.